Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Synthetic Fungal Compounds Show Potent Anticancer Potential

By BiotechDaily International staff writers
Posted on 12 Mar 2013
Recent advances in the chemical synthesis of rare fungal compounds have yielded an exciting new class of reagents with potent anticancer properties.

Investigators at the Massachusetts Institute of Technology (Cambridge, MA, USA) have been working with a class of fungal compounds called epipolythiodiketopiperazine (ETP) alkaloids. However, until recently the small amounts of these compounds that are produced naturally have made it difficult to do a comprehensive study of the relationship between the compounds' structure and their activity.

In a paper published in the January 24, 2013, online edition of the journal Chemical Science the investigators reported the development and application of a flexible and scalable synthetic technique, which allowed the construction of dozens of ETP derivatives.

Sixty of these compounds were tested against two different human cancer cell lines—cervical cancer and lymphoma. Many ETP derivatives demonstrated potent anticancer activity and killed cancer cells via induction of apoptosis. The most effective 25 compounds were tested against three additional lines, from lung, kidney, and breast tumors.

Overall, dimeric compounds appeared to be more effective at killing cancer cells than monomers, and compounds with at least two sulfur atoms were more effective than those with only one sulfur atom. Compounds lacking sulfur did not kill tumor cells efficiently. The active compounds were found to be approximately 1,000 times more toxic to cancer cells than they were to normal cells.

Several traits that bode well for the translational potential of the ETP class of natural products include concise and efficient synthetic access, potent induction of apoptotic cell death, activity against a wide range of cancer types, and a broad tolerance for modifications at multiple sites that should facilitate small-molecule drug development, mechanistic studies, and evaluation in vivo.

"What was particularly exciting to us was to see, across various cancer cell lines, that some of them are quite potent," said first author Dr. Mohammed Movassaghi, professor of chemistry at the Massachusetts Institute of Technology. "There is a lot of data out there, very exciting data, but one thing we were interested in doing is taking a large panel of these compounds, and for the first time, evaluating them in a uniform manner. We can go in with far greater precision and test the hypotheses we are developing in terms of what portions of the molecules are most significant at retaining or enhancing biological activity."

Related Links:

Massachusetts Institute of Technology



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A leukemia cell coated with antibody is marked for destruction by activated natural killer cells (Photo courtesy of the University of Southern California).

Leukemia Cells Are Killed in Culture by Immune Cells Grown from the Same Patient

Immune system natural killer (NK) cells were isolated from leukemia patients, expanded in culture, and then shown in an in vitro system to attack and destroy cancer cells from the original cell donors.... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

White-Matter Deficits Found in Codeine-Containing Cough Syrup Users

A magnetic resonance imaging (MRI) study of chronic users of codeine-containing cough syrups (CCS) has found deficits in specific regions of brain white matter and linked these changes with increased impulsivity in codeine-containing cough syrup users. These findings were consistent with findings from earlier research of... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.